Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $365.2052W HIGH $557.00
Volume
134.46 K
Value Traded
65.11 M
Short % Float
5.1%
-2.25%Week
-2.83%1 Month
+1.53%3 Month
+28.95%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.53 B
EPS (TTM)
21.04
P/E Ratio
23.76
Ent. Value
6.63 B
Total Shares
13.07 M
Float Shares
12.82 M
Insiders
1.89%
Institutions
105.77%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CHE Catalyst Timeline
Dated clinical, regulatory and corporate events for Chemed Corporation
Past FDA Catalysts and PDUFA Decisions
How CHE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Chemed Corporation is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CHE program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| LEE SPENCER SOfficer (executive vice president) | Option | 12,099 26,011 held | $445.35 | 09/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CHE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 0.4 % | 1.30 M | 2.50 K |
CHE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CHE ranks across every disease it competes in
Competitive Position is a premium feature
See how CHE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCHE News
-CHE
Oct 1, 2026Chemed To Report Third Quarter 2026 Earnings October 27, Related Conference Call To Be Held On October 28
Chemed Corporation will release its financial results for the third quarter of 2026 on October 27, followed by a conference call on October 28 to discuss the results and provide business updates. The call will be accessible via webcast and teleconference, with a replay available afterward. Chemed operates in hospice care and plumbing services through its subsidiaries.
Read more →-CHE
Aug 6, 2026Chemed Corporation Declares Quarterly Dividend of 70 Cents
Chemed Corporation has declared a quarterly cash dividend of 70 cents per share, marking a 17% increase from the previous dividend of 60 cents. This dividend is set to be paid on September 3, 2026, to shareholders of record as of August 17, 2026. This announcement highlights Chemed's commitment to returning value to its shareholders, continuing a streak of 221 consecutive quarterly dividends.
Read more →-CHE
Jul 28, 2026Chemed Reports Second-Quarter 2026 Results
Chemed Corporation reported strong financial results for the second quarter of 2026, with revenue increasing by 8.8% to $673.3 million and GAAP diluted earnings per share rising by 43.7%. The VITAS segment experienced significant growth, particularly in net patient revenue and admissions. However, the Roto-Rooter segment faced challenges with flat adjusted EBITDA and a decline in water restoration revenue. The company has revised its full-year earnings guidance upward, reflecting improved performance.
Read more →-CHE
Jul 1, 2026Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29
Chemed Corporation will announce its second quarter financial results on July 28, 2026, after market close. A conference call to discuss these results will take place on July 29, 2026, at 10 a.m. ET. Participants can join via webcast or teleconference, and a replay will be available shortly after the call.
Read more →-CHE
May 13, 2026Chemed Corporation to Present at the 2026 RBC Global Healthcare Conference
Chemed Corporation announced its participation in the RBC Capital Markets Global Healthcare Conference on May 20, 2026. The presentation will take place at 8:30 a.m. ET at The InterContinental New York Barclay Hotel. An audio webcast will be available on the company's website, with a replay accessible for 90 days.
Read more →-CHE
May 5, 2026Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2026
Chemed Corporation will present at the Bank of America Securities 2026 Health Care Conference on May 12, 2026. The event will take place at the Encore at the Wynn Las Vegas and will be available via live webcast. Chemed operates VITAS Healthcare and Roto-Rooter, leaders in hospice care and plumbing services, respectively.
Read more →-CHE
Apr 23, 2026Chemed Reports First-Quarter 2026 Results
Chemed Corporation reported its first-quarter 2026 results, showing a revenue increase in its VITAS segment and notable growth in admissions. The company also raised its full-year guidance due to stronger-than-anticipated performance, leading to improved revenue and adjusted EBITDA projections. In contrast, Roto-Rooter faced a slight revenue decline attributed to service disruptions and higher marketing costs. The company remains optimistic about future growth, highlighted by a significant share repurchase program.
Read more →-CHE
Apr 13, 2026Chemed Corporation Announces a Five-Year $450 Million Amended and Restated Credit Agreement
Chemed Corporation has announced a five-year amended and restated credit agreement worth $450 million. This agreement includes a revolving credit facility and an option to expand by an additional $250 million. The interest rate is tied to the secured overnight financing rate (SOFR). Chemed operates two subsidiaries, VITAS Healthcare and Roto-Rooter.
Read more →-CHE
Feb 26, 2026▼ -15%on this news
Chemed Reports Fourth-Quarter 2025 Results
Chemed Corporation reported its fourth-quarter results for 2025, showing mixed performance across its segments. VITAS Healthcare saw a 1.9% increase in revenue, driven by higher admissions and Medicare reimbursement rates, while Roto-Rooter experienced a revenue decline of 3.7%. The company remains debt-free and has plans for revenue growth in 2026, despite challenges in the Roto-Rooter segment.
Read more →-CHE
Jan 5, 2026Chemed to Report Fourth-Quarter 2025 Earnings February 25, Related Conference Call to Be Held on February 26
Chemed Corporation will release its fourth-quarter earnings for 2025 on February 25, 2026. A conference call is scheduled for February 26, 2026, to discuss the results and provide business updates. Investors can access the call via webcast or teleconference, with a replay available shortly after the event.
Read more →-CHE
Oct 28, 2025Chemed Reports Third-Quarter 2025 Results
Chemed Corporation reported its third-quarter 2025 results, showing a positive 4.2% revenue increase for its VITAS segment, driven by higher admissions. Roto-Rooter also experienced a modest revenue rise of 1.1%. However, the company faced challenges with declining gross margins and adjusted EBITDA for both segments. Chemed reiterated its guidance for the year, projecting earnings per share between $22.00 and $22.30, contingent on Medicare-related conditions.
Read more →-CHE
Jul 29, 2025Chemed Reports Second-Quarter 2025 Results and Announces Executive Management Departure
Chemed Corporation reported its second-quarter 2025 results, highlighting a 5.8% increase in VITAS net revenue, driven by admissions and Medicare reimbursement rate improvements. However, the company revised its full-year earnings guidance downwards significantly, attributing this to projected Medicare Cap billing limitations and weaker admissions in Florida. Additionally, the departure of CEO Nicholas M. Westfall, who will stay until December for a transition, adds to the company's uncertainties. Despite these challenges, Chemed maintains a strong cash position and is actively continuing its share repurchase program.
Read more →-CHE
Jun 27, 2025Chemed To Report Second-Quarter 2025 Earnings July 29, 2025
Chemed Corporation plans to report its second-quarter 2025 earnings on July 29, 2025. The announcement includes insights into its VITAS subsidiary, which is expecting a Medicare Cap revenue limitation due to weaker admissions than projected in Florida. However, VITAS has received a Certificate of Need to expand into Pinellas County, indicating potential for future growth. Additionally, Roto-Rooter has experienced unexpected weakness in its residential services, contrasting with improving trends in its commercial segment.
Read more →-CHE
Apr 23, 2025Chemed Reports First-Quarter 2025 Results
Chemed Corporation reported strong first-quarter results for 2025, with VITAS segment revenues increasing by 15.1% year-over-year. The company attributed $11.5 million to $12.5 million in revenue to the recent acquisition of Covenant Health's hospice assets. Roto-Rooter, while generating overall increased revenue, faced challenges with declines in certain service areas. The company maintains a robust cash position with no debt and plans to provide updated earnings guidance later in the year.
Read more →-CHE
Feb 26, 2025Chemed Reports Fourth-Quarter 2024 Results
Chemed Corporation reported its fourth-quarter 2024 financial results, noting a 17.4% revenue increase in its VITAS segment while Roto-Rooter saw a 2.9% decline. The VITAS acquisition of Covenant Health contributed approximately $11 million to revenue, resulting in a modest net income increase. Adjusted EBITDA for VITAS rose by 11.8%, but the overall gross margin decreased slightly compared to last year. Admissions for VITAS were negatively impacted by recent hurricanes, estimated to have affected around 150-175 patients.
Read more →-CHE
Oct 29, 2024Michael D. Witzeman (513) 762- 6714 Chemed Reports Third -Quarter 2024 Results CINCINNATI
Chemed Corporation reported its third-quarter 2024 financial results, highlighting a 17.3% increase in VITAS revenue compared to the previous year. The company also noted challenges in its Roto-Rooter segment, which saw a 6.9% decline in quarterly revenue. Despite environmental impacts from Hurricane Helene causing a temporary slowdown in patient admissions, Chemed maintained a strong cash position without debt. The company reaffirmed its earnings guidance for 2024, indicating a positive outlook amidst challenges.
Read more →-CHE
Jul 24, 2024Michael D. Witzeman (513) 762- 6714 Chemed Reports Second-Quarter 2024 Results CINCINNATI
Chemed Corporation has reported its financial results for the second quarter of 2024, highlighting a significant revenue increase in its VITAS segment, attributed to an acquisition and improved operational metrics. The company anticipates a notable contribution from the recently acquired Covenant Health assets, projecting a continued positive trend for VITAS. However, Roto-Rooter faced revenue declines in both commercial and residential sectors, which the company expects to persist into 2024. Adjusted EBITDA from VITAS saw a substantial increase, further strengthening Chemed's financial outlook.
Read more →About Chemed Corporation
HeadquartersSUITE 2600, CINCINNATI, OH, 45202
BIOPHARMAWATCH ELITE PLUS
Trade the next CHE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime